KIP2 protein is a cell cycle inhibitor and tumor suppressor encoded by a strongly paternally imprinted gene. We explored the utility of p57 KIP2 as a diagnostic marker in hydatidiform mole, a disease likely the result of abnormal dosage and consequent misexpression of imprinted genes. Using a monoclonal antibody on paraffin-embedded, formalin-fixed tissue sections, the authors evaluated p57 KIP2 expression in normal placenta and in 149 gestations including 59 complete hydatidiform moles, 39 PHMs, and 51 spontaneous losses with hydropic changes. p57 KIP2 was strongly expressed in cytotrophoblast and villous mesenchyme in normal placenta, all cases of partial hydatidiform moles (39 of 39) and all spontaneous losses with hydropic changes (51 of 51). In contrast, p57 KIP2 expression in cytotrophoblast and villous mesenchyme was absent or markedly decreased in 58 of 59 complete hydatidiform moles. In all gestations p57 KIP2 was strongly expressed in decidua and in intervillous trophoblast islands, which served as internal positive controls for p57 KIP2 immunostaining. p57 KIP2 immunohistochemistry can reliably identify most cases of complete hydatidiform mole irrespective of gestational age and is thus a useful diagnostic adjunct, complementary to ploidy analysis, in the diagnosis of hydatidiform mole.
The histopathologic diagnosis of hydatidiform mole is difficult, with significant interobserver variation in the distinction between complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), and spontaneous abortion (SA). 5, 17 Although histologic criteria are used to distinguish CHM from PHM in most cases, histologic features can have significant overlap, especially in early gestations, 12 and SAs can exhibit hydropic changes or trophoblast hyperplasia that mimic hydatidiform mole. 20 These difficulties have intensified in recent practice because of the increasing use of prenatal screening techniques such as ␤-human chorionic gonadotropin (hCG) measurements and ultrasonography that permit earlier clinical recognition and termination of abnormal pregnancies including hydatidiform moles. 18, 21 Because most CHMs are diploid whereas most PHMs are triploid, ploidy analysis by flow cytometry or other methods is a useful diagnostic aid to identify PHMs 15 ; however, ploidy analysis cannot be used to distinguish CHM from nonmolar gestation. Analysis of polymorphic short tandem DNA repeats by polymerase chain reaction (PCR) can identify CHM and PHM but is technically cumbersome and difficult to standardize. 2, 8 Because CHMs are associated with a high incidence of persistent disease and choriocarcinoma whereas PHMs behave in a malignant fashion very infrequently, 22 the lack of an adjunct test to confirm the diagnosis of CHM is a significant limitation in current practice.
CHMs are derived exclusively from paternal DNA, whereas PHMs contain one maternally derived and two paternally derived haploid genomes, 11, 16, 26 suggesting that both CHM and PHM are the result of abnormal expression of imprinted genes. 6 While the vast majority of genes are expressed equally from maternal and paternal copies, approximately 40 human genes are imprinted-expressed from only the paternal or maternal allele, with the other allele transcriptionally silent. Genomic imprinting involves differential DNA methylation of maternal and paternal alleles leading to allele-specific expression through complex mechanisms currently under investigation. The p57 KIP2 gene is strongly paternally imprinted, being expressed predominantly from the maternal allele in most tissues. 24 Because CHMs contain only paternal DNA, p57 KIP2 should be underexpressed in CHMs. In contrast, because all other types of gestations including PHMs contain maternal DNA, the pattern of p57 KIP2 expression should be essentially normal in nonCHMs. Recently, one study presented immunohistochemical evidence that p57 KIP2 is differentially expressed in molar versus nonmolar gestations. 4 The current report describes the results of a comprehensive study designed to assess the value of p57 KIP2 immunohistochemistry in the diagnosis of a wide range of molar and nonmolar gestations.
MATERIALS AND METHODS

Case Selection
Cases of CHM, PHM, and SA with hydropic changes were randomly selected from the files of the Pathology Department of the Brigham and Women's Hospital (1995) (1996) (1997) (1998) (1999) (2000) . Histologic evaluation of all cases was performed on routine sections stained with hematoxylin and eosin; diagnoses were made by gynecologic pathologists using published criteria. 12, 19 The diagnosis in each case (CHM, PHM, or SA) for the purpose of this study was taken from the original pathology report. Ancillary studies (flow cytometry on fresh tissue or karyotyping) had been performed in the original diagnostic workup of 40% of cases diagnosed as hydatidiform moles. The gestational age for CHMs ranged from 5 to 22 weeks and was <10 weeks in more than half of the cases; 24 of 59 CHMs were confirmed diploid or tetraploid by flow cytometry or cytogenetic analysis, whereas 35 CHMs were not evaluated. Included in our 59 cases of CHM were two invasive moles confirmed after hysterectomy and 10 recurrences in patients with previously diagnosed CHM. The gestational age for PHMs ranged from 7 to 19 weeks; 16 of 39 PHMs were confirmed to be triploid, whereas 23 PHMs were not evaluated. Cases identified as SA were specimens noted to have hydropic change in the original pathology report. Of the 51 cases of SA, eight cases had karyotypic abnormalities involving single chromosome gains or losses. Mature and immature placentas (three cases each) were randomly selected among normal term gestations or elective terminations.
Antibodies and Immunohistochemistry
Mouse monoclonal antibodies against the p57 KIP2 protein were obtained from NeoMarkers/Lab Vision Corporation (Fremont, CA, USA). We used a ready-touse preparation without dilution (catalog no. MS-1062-R7) or a concentrated preparation (catalog no. MS-1062-P1) at 1:200 dilution with similar results. Only formalinfixed, paraffin-embedded tissue was studied. Antigen retrieval was performed at 93°in 10 mM sodium citrate buffer pH 6.0 for 30 minutes with a 10-minute cooldown. The detection system was StreptABC (Dako Corporation, Carpinteria, CA, USA) with diaminobenzidine as the chromogen. The slides were counterstained with hematoxylin. Only distinct nuclear staining was scored as positive. For all cases the presence or absence of nuclear staining was assessed in five cell types (villous mesenchyme [VM], cytotrophoblast [CT], syncytiotrophoblast [ST], intervillous trophoblast, and decidua), blinded to the original diagnosis and independent of the hematoxylin and eosin histologic appearance.
DNA Analysis and Fluorescence In Situ Hybridization
DNA analysis and ploidy determination were performed on one case of CHM, as described in Results. Sections were cut from a block of paraffin-embedded, formalin-fixed tissue. An unstained 6-m section was oriented by referring to a paired consecutive section stained with hematoxylin and eosin, and areas of molar villi and maternal decidua were identified. DNA was then prepared from this tissue, amplified by the PCR, and analyzed as described. 7 The microsatellite repeats analyzed were D1S1656, D5S816, D7S440, D9S43, D10S179, D15S659, and D18S535 (Human Genome Database, Toronto, Ontario, Canada: Hospital for Sick Children; Baltimore, MD, USA: Johns Hopkins University, http://www.gdb.org). Fluorescent in situ hybridization of interphase nuclei from suspensions prepared from 50-m paraffin sections was performed essentially as described.
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RESULTS
p57
KIP2 Expression in Normal Placenta, SA With Hydropic Change, and PHM
In normal placenta p57
KIP2 was strongly expressed in CT, VM, and in intervillous trophoblast islands (IVTI), whereas the ST was uniformly negative. In both immature (first trimester) and mature (term) placenta, a significant proportion of CT, IVTI, and VM nuclei (at least 30%) were strongly p57 KIP2 positive (Fig. 1A, B) . We also evaluated an early gestational sac (approximately 3 weeks), which can be mistaken for a cavitated molar villus. In this early gestation the VM was strongly p57 KIP2 positive; staining was weak in CT and absent in ST (Fig. 1C) . In fragments of gestational endometrium secretory glands were negative, but many stromal (i.e., decidual) cells were strongly positive, in roughly equal intensity to that observed in the CT, IVTI, and VM (Fig. 1D) .
In all SAs (51 cases) and all PHMs (39 cases), the staining pattern was similar to that seen in normal placenta, with strong p57 KIP2 expression in the CT and VM (Fig. 1E, F) . In areas of stromal edema the density of positive VM cells was lower than in nonedematous areas, but the proportion of positive nuclei was unchanged. In PHMs two discrete populations of villi (sclerotic or edematous) are usually present. p57 KIP2 staining was similar in PHM villi irrespective of their morphology (not shown).
p57 KIP2 Expression in CHM
In contrast to both PHM and SA, almost all cases of CHM exhibited a striking lack of p57 KIP2 expression in both CT and VM (Fig. 1G) . In the majority of CHM villi expression of p57 KIP2 in VM and CT was virtually absent. However, focal CT positivity was present in some CHMs, with occasional villi exhibiting a small number of positive CT cells (1-3 cells in most cases but up to 12 cells in one villus in one case) (Fig. 1H ). Despite this, the overall scarcity of p57 KIP2 positive CT cells in CHM compared with PHM or SA (<0.1% of CT vs 30%) appears to readily permit the discrimination of CHM from PHM or SA in most instances. p57 KIP2 was equally diagnostic in early CHM (Fig. 1I ) and other CHM variants including invasive CHM and recurrent/persistent CHM (not shown). Notably, p57 KIP2 CT and VM expression was absent or dramatically decreased even in CHM villi with minimal trophoblast hyperplasia or stromal changes (e.g., Fig. 1I ). In all cases most IVTI nuclei were strongly positive and together with maternal decidua served as an internal positive control for p57 KIP2 immunostaining (Fig. 1G , left third of panel). In summary (with the exception of the single case described below), CHM could be readily distinguished from PHM or SM by evaluation of p57 KIP2 expression in the CT and VM. The difference in p57 KIP2 CT and VM positive immunostaining in CHM (1 of 59) versus non-CHM (90 of 90) in our cases was highly statistically significant (p value ֈ 10 −41 , Fisher exact test) (summarized in Table 1 ). One of 59 cases diagnosed as CHM exhibited diffuse VM and CT positivity, indistinguishable from the staining pattern of PHM and SA (Fig. 1J) . This pregnancy, which represented the mother's third, was terminated at a gestational age of 10 weeks; there was no antecedent history of hydatidiform mole. All slides for this case were reviewed, and the histologic features including significant trophoblast hyperplasia and diffuse villous cavitation confirmed CHM. Flow cytometry on fresh tissue had indicated a diploid DNA content, consistent with a CHM. To confirm this result, we performed fluorescence in situ hybridization using probes corresponding to chromosomes X, Y, 8, 11, and 18. The results demonstrated that the lesion was diploid for chromosomes X, 8, 11, and 18 (no Y signal was observed) again consistent with a CHM. To confirm that the lesion was androgenetic (and therefore a CHM), both the lesion (using DNA prepared from molar villi) and the patient (using DNA from decidual tissue) were genotyped for seven microsatellite markers on different chromosomes. The lesion was clearly androgenetic for four of the markers, having no alleles in common with the patient. Of the seven markers examined, the CHM was homozygous for five markers but heterozygous for two, indicating that this was a dispermic CHM.
DISCUSSION
In CHMs, which lack nuclear DNA of maternal origin, strongly paternally imprinted genes should in principle be significantly underexpressed or not expressed at all. Consistent with this view, we find that p57 KIP2 is strikingly underexpressed in the CT and VM of CHM, but not in PHM and SA, and that this underexpression can serve as the basis for a reliable diagnostic test to identify CHM. Because PHMs have one set of maternally derived chromosomes, the underexpression of p57 KIP2 in PHM should be comparatively slight and probably not detectable by immunohistochemistry. Although other paternally imprinted genes could serve as useful markers to identify CHM, p57 KIP2 seems especially well suited for this purpose because: 1) it is strongly expressed in normal placenta throughout gestation, and its staining pattern in CHM, PHM, and SA appears to be similarly independent of gestational age; and 2) internal positive controls for p57 KIP2 immunostaining (IVTI and maternal decidua) are always present in clinical specimens. Because we evaluated a large number of cases and used a commercially available monoclonal antibody, our findings significantly expand upon an earlier study that documented the expression of p57 KIP2 in normal placental cell types and suggested the potential utility of p57 KIP2 immunohistochemistry in gestational trophoblastic disease. 4 
p57
KIP2 is a potent cell cycle inhibitor and tumor suppressor, and lack of p57 KIP2 activity can lead to loss of cell cycle control and hyperproliferation. 27 Therefore, underexpression of p57 KIP2 likely contributes to the molar phenotype including histologic correlates such as trophoblast hyperplasia. Consistent with this, the Beckwith-Wiedemann syndrome, which is associated with loss or point mutation of the maternal p57 KIP2 allele, is characterized by fetal/placental overgrowth, predisposition to tumors, and placental abnormalities that can resemble those observed in hydatidiform mole. 14 Furthermore, mouse embryos deficient for p57 KIP2 exhibit placentomegaly with significant trophoblast hyperplasia and dysplasia. 23 However, the fact that patients with Beckwith-Wiedemann syndrome do not develop frank hydatidiform moles strongly suggests that misregulation of other imprinted genes also contributes to the molar phenotype.
The expression of p57 KIP2 in CHM IVTI, although useful as an internal positive control, was unanticipated. This expression likely reflects incomplete or relaxed imprinting of p57 KIP2 , as some imprinted genes are not expressed exclusively from a single allele in all tissues. 3, 25 For example, the human GRB10 gene is imprinted in a highly isoform-and tissue-specific manner. In fetal brains most GRB10 variants are transcribed exclusively from the paternal allele, whereas in skeletal muscle one splice variant is expressed from the maternal allele, and in other tissues all splice variants are transribed from both parental alleles. 3 Intriguingly, another paternally imprinted gene expressed in placenta, H19 (which encodes a nontranslated RNA), is expressed in a similar pattern as p57 KIP2 in normal placenta and is also expressed in IVTI in CHM. 1 The alternative explanation for the observed expression of p57 KIP2 in CHM IVTI, that of cross-reactivity of the monoclonal antibody with a related protein such as p27 KIP1 or an unrelated protein, seems unlikely because of the very limited extent of similarity between p57 KIP2 and p27 KIP1 at the amino acid level and because the staining in IVTI is nuclear, as expected for p57 KIP2 . Similarly, the expression of p57 KIP2 observed in rare CT of CHM may also be due to incomplete or relaxed imprinting.
Of 59 cases diagnosed as CHM, only one exhibited p57 KIP2 expression in a significant proportion of CT and VM. Interestingly, the p57 KIP2 staining pattern in this case was completely unlike all other CHMs in our series and indistinguishable from PHM and SA. It is clearly not a PHM, as the lesion was found to be diploid by two separate methodologies, and DNA analysis confirmed that the lesion was androgenetic and therefore a CHM. The underlying basis for p57 KIP2 expression in this CHM remains unclear. Although the lesion is diploid for a centromeric chromosome 11 probe by fluorescent in situ hybridization (the p57 KIP2 locus maps to chromosome 11p15.5), it remains formally possible that a maternal chromosomal fragment containing the 11p15.5 region was retained, leading to p57 KIP2 expression from a maternal copy of the locus. Perhaps more likely, p57 KIP2 was, for unknown reasons, abnormally imprinted in the ontogenesis of this lesion. It is also notable that this lesion is XX and dispermic because 90% of CHMs are monospermic and only about 5% of CHMs are XX and dispermic. 9 Our results indicate that although p57 KIP2 is a highly specific and sensitive marker of CHM, false-negative results are possible. The results of p57 KIP2 immunostaining should thus be interpreted in conjunction with morphologic features and all other available information. We identified no false positives in our series, but additional studies will be required to determine the true specificity and sensitivity of p57 KIP2 immunostaining. Because p57 KIP2 immunostaining is highly accurate in the diagnosis of hydatidiform mole, confirmation of p57 KIP2 false positives and false negatives by other methods including ploidy and DNA analysis will be necessary.
The monoclonal antibody against p57 KIP2 used in this study worked reliably on paraffin-embedded, formalinfixed tissue, with strong immunoreactivity of internal positive controls in the 149 archival cases studied. Therefore, this antibody appears to be well suited for use as a diagnostic test of clinical specimens as collected and processed in routine practice. p57 KIP2 immunostaining, although complementary to flow cytometry, may offer some advantages. First, it does not require collection of fresh tissue. Flow cytometry can be performed on paraffin sections, 10 but the results can be difficult to interpret, particularly if abundant tissue of maternal origin is present. Second, although a triploid flow cytometry result confirms the suspicion of a PHM, a diploid result can leave some doubt that contaminating maternal tissue had been inadvertently sent for analysis. Because p57 KIP2 immunostaining is an in situ technique performed on paraffin-embedded tissue, it largely avoids these problems. Lastly, p57
KIP2 positively identifies CHM, a lesion that has a much higher risk of progression and choriocarcinoma than PHM. In conclusion, our study shows that p57 KIP2 immunostaining is a practical and accurate adjunct in the diagnosis of hydatidiform mole.
ᮀ
Addendum
Analysis of microsatellite DNA repeats in the single p57KIP2 positive CHM has revealed that although it is diploid for all markers on the 11q arm and other chromosomes (as expected), at least one marker on chromosome 11p is triploid, suggesting that the aberrant expression of p57KIP2 in this CHM is the result of retention of a portion of the maternal chromosome 11p containing the p57KIP2 locus.
